H2 2025 catalysts to watch, biopharma implications of President Trump’s tax law, KalVista’s new hereditary angioedema drug that Marty Makary reportedly tried to reject, another lawsuit aimed at Health ...

BofA raised the firm’s price target on KalVista (KALV) to $37 from $22 and keeps a Buy rating on the shares after the company announced the approval of Ekterly for on-demand treatment of hereditary ...

The United States market remained flat over the last week, but it has risen 13% over the past 12 months with earnings forecasted to grow by 15% annually. In this context, identifying high growth tech ...

The White House’s plans to make significant cuts to funding from NIH is expected to have significant impact on the pharma industry for years to come. Justin Kozak, an executive VP at Founder Shield, ...